Get the Stockscreener App
306.97
0.34%
-1.05
After Hours:
306.97
United Therapeutics Corp stock is traded at $306.97, with a volume of 223.15K.
It is down -0.34% in the last 24 hours and down -5.14% over the past month.
See More
Previous Close:
$308.02
Open:
$309.58
24h Volume:
223.15K
Relative Volume:
0.55
Market Cap:
$14.37B
Revenue:
$2.76B
Net Income/Loss:
$1.11B
P/E Ratio:
13.48
EPS:
22.77
Net Cash Flow:
$898.10M
1W Performance:
-1.92%
1M Performance:
-5.14%
6M Performance:
-14.38%
1Y Performance:
+33.63%
1-Day Range:
$304.03
$309.58
1-Week Range:
$304.03
$322.32
52-Week Range:
$221.53
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
306.97 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics: Don't Fear The Patent Expiration Too Much (NASDAQ:UTHR) - Seeking Alpha
Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March? - Insider Monkey
United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
United Therapeutics director sells $796,990 in stock By Investing.com - Investing.com Australia
United Therapeutics director sells $796,990 in stock - Investing.com
First Week of November 21st Options Trading For United Therapeutics (UTHR) - Nasdaq
United Therapeutics director sells $1.55 million in stock By Investing.com - Investing.com Canada
United Therapeutics director sells $1.55 million in stock - Investing.com India
Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside - Investing.com
United Therapeutics price target lowered to $314 from $328 at BofA - TipRanks
Exosome Therapy Market Market Is Booming Worldwide 2025-2032 | - openPR
Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia
For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review
United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com
What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan
Top Executives Cash In on United Therapeutics Stock! - TipRanks
Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com
United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada
United Therapeutics director Thompson sells $795,837 in stock - Investing.com India
Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow
Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World
Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Receives FDA Approval for Pig Organ Clinical Trials - Source of the Spring
United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat
Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares - MarketBeat
Atria Wealth Solutions Inc. Invests $412,000 in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics price target lowered to $420 from $430 at Leerink - Yahoo Finance
Lung transplant technology collaboration between Mayo Clinic Florida and United Therapeutics - Florida Trend
United Therapeutics Corp. Reports Record Revenue and Growth - TipRanks
United Therapeutics Corp. to Host Earnings Call - ACCESS Newswire
United Therapeutics Reports Record Revenue in Q4 2024, Advances Strategic Growth - HPBL
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript - Insider Monkey
Goldman Sachs cuts United Therapeutics stock target to $293 By Investing.com - Investing.com Australia
Goldman Sachs cuts United Therapeutics stock target to $293 - Investing.com
United Therapeutics: Q4 Earnings Snapshot - Thehour.com
United Therapeutics Corp (UTHR) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus.com
United Therapeutics Reports Record 2024 Financial Results - TipRanks
United Therapeutics Enters Oversold Territory (UTHR) - Nasdaq
United Therapeutics (UTHR) Shares Cross Below 200 DMA - Nasdaq
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat - Yahoo Finance
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):